Please login to the form below

Not currently logged in
Email:
Password:

RNA-focused biotech Storm Therapeutics raises extra £14m

New head of translational oncology also hired

storm

Storm Therapeutics, the UK-based biotech specialising in modulating RNA modifying enzymes has announced that it has raised an extra £14m ($17.8m) from investors.

The additional funds come from Dublin-based life science venture capital firm  Seroba Life Sciences, and brings the biotech’s total Series A financing to £30m.

The new money adds to existing investment from Cambridge Innovation Capital, M Ventures, Pfizer Ventures, Taiho Ventures and IP Group, who also took part in the fundraising.

First set up in 2015 by epigenetics and RNA specialists Professor Tony Kouzarides and Professor Eric Miska, the Cambridge-based company has a pipeline of early-stage molecules in development in oncology and other disease areas.

The company says the new funds will help it advance its broad pipeline towards the clinic, with the platform based on RNA modulating enzymes. This is a new approach to the RNA therapeutics field, where Alnylam has pioneered a 'RNA silencing' modality.

STORM has also just hired  Mark Albertella as vice president of translational oncology.  Previously director of biology at Medivir, Albetella has a successful track record in oncology drug discovery and development at Argenta, OSI Pharmaceuticals, Kudos and AstraZeneca.

Keith Blundy

Keith Blundy

Dr Keith Blundy, chief executive of Storm Therapeutics, said: This investment strengthens our Series A and provides further validation and support for Storm’s strategy to continue building a world-leading company harnessing the power of RNA epigenetics - an emerging, innovative area of drug discovery. It comes at an exciting stage as Storm starts translating its unique platform into effective treatments in oncology and beyond.

Bruno Montanari, partner at Seroba, added: “We have been closely following the RNA space for some time tracking a number of key players. We believe Stormis maintaining its first-mover advantage in RNA epigenetic modulation and is progressing rapidly in its development, making this an exciting time for us to partner with management and co-investors. We continue to be impressed by the quality and depth of Storm’s science and the significant progress made by the team to advance its platform and pipeline in this fast-moving area of emerging biology.”

Article by
Andrew McConaghie

20th May 2019

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

Personalised medicine: driving a need for greater diversity in clinical trials
Kate Shaw, Innovative Trials' Founder & CEO, investigates one of the biggest challenges facing clinical research today....
Congresses and conferences
Superstar congresses and conferences will stay centre stage but now share the limelight with virtual and hybrid events
With the pandemic having dimmed the lights on pharma conferences, their virtual and hybrid replacements have grasped the opportunity and are here to stay...
Cervical Cancer Prevention Month
In this first 2022 blog, the Innovative Trials' Equality & Diversity committee will be looking at raising awareness around Cervical Cancer...